This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
CADTH. Apixaban and rivaroxaban for stroke prevention in atrial fibrillation: safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Reference List. 2014
Twenty-two systematic reviews/meta-analyses, 24 randomized controlled trials, and three non-randomized studies were identified regarding adverse events associated with the use of apixaban and rivaroxaban.
Subject indexing assigned by CRD
Anticoagulants; Atrial Fibrillation; Humans; Morpholines; Pyrazoles; Pyridones; Stroke; Thiophenes
Country of organisation
An English language summary is available.
Address for correspondence
Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: email@example.com
Date abstract record published